Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing pharmaceutical products for patients suffering from cancer or pain. The Company has two FDA approved drugs, SUSTOL and CINVANTI, for the prevention of chemotherapy-induced nausea and vomiting (CINV). The Company’s lead candidate, HTX-011, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of postoperative pain. HTX-011 was designed to provide superior pain relief while potentially reducing the need for systemically administered pain medications such as opioids